Insider Transactions in Q4 2022 at Biomarin Pharmaceutical Inc (BMRN)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,500
-8.27%
|
$267,500
$107.5 P/Share
|
|
Dec 13
2022
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+7.63%
|
$157,500
$63.1 P/Share
|
|
Dec 13
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.31%
|
$106,000
$106.89 P/Share
|
|
Dec 02
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,500
-0.09%
|
$154,500
$104.0 P/Share
|
|
Dec 02
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,001
-7.64%
|
$728,104
$104.5 P/Share
|
|
Dec 02
2022
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,900
+8.67%
|
$395,300
$67.81 P/Share
|
|
Nov 23
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,379
-5.68%
|
$527,142
$98.03 P/Share
|
|
Nov 23
2022
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+9.76%
|
$234,500
$67.81 P/Share
|
|
Nov 02
2022
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
100
+0.03%
|
$8,600
$86.12 P/Share
|
|
Nov 02
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.8%
|
$258,000
$86.12 P/Share
|
|
Oct 31
2022
|
Mark J Alles Director |
BUY
Open market or private purchase
|
Direct |
3,625
+24.95%
|
$311,750
$86.75 P/Share
|
|
Oct 31
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,500
-0.46%
|
$129,000
$86.55 P/Share
|
|
Oct 14
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
4,000
-1.22%
|
$356,000
$89.89 P/Share
|